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tases	 additionally	 identified	by	nirf	 are	 indicative	of	otherwise	undetectable,	
widespread	metastases	 in	the	 liver	or	 if	patients	are	 in	fact	cured	by	resecting	

















potential	to	visualize	multiple	tumor	types.	Several	nonclinical	in vitro	and	in vivo 
experiments	are	required	prior	to	a	first-in-human	study.	Chapter 10	discusses	































































[2,	3].	Pancreatic	cancer	surgery	 is	only	conducted	when	there	 is	a	 reasonable	








adjuvant	 therapy	 [6-9].	The	 combination	of	 endoscopic	ultrasonography	 (eus)	


































assessment	 of	 pancreatic	 tumor	 extension,	 enhanced	 or	 novel	 intraoperative	
imaging	 technologies	 accurately	 visualizing	 and	 delineating	 cancer	 cells	 are	
necessary.	 Emerging	 modalities	 are	 intraoperative	 near-infrared	 fluorescence	






























































































Besides	 fluorophores,	 ligands	 can	 also	 be	 conjugated	 to	 radiotracers,	 which	
are	 directed	 to	 tumor-specific	 biomarkers	 eliciting	 tumor	 specific	 signals	
and	 enhancing	 tumor	 visualization	 (Figure	 1d).	 These	 radioactive	 ligands	 are	





antibody	 from	 the	body)	 and	difficulties	 in	handling	and	disposing	 the	 radio-




















Intraoperative	 imaging	 modalities,	 which	 can	 accurately	 depict	 pancreatic	






























Until	 now,	 no	membrane-bound	biomarkers	 are	 validated	 in	 the	 clinic,	 but	
recent	literature	show	very	promising	results	in	preclinical	studies.	Various	forms	























Fluorescence-guided	 laparoscopy	 during	 hepatopancreatobiliary	 surgery	 has	
already	shown	its	potential	to	improve	intraoperative	identification	and	demar-
cation	 of	 tumors	 [85].	 Remaining	 fluorescence	 signal	 in	 the	 resection	 wound	
can	be	an	indication	of	irradical	resection,	which	may	make	ifsa	redundant.	To	
date,	no	 in-human	 trials	have	been	done	with	pancreatic	 cancer	 specific	 con-
trast	 agents,	 but	 preclinical	 studies	 are	 very	 promising.	A	major	 restriction	 of	
nir	fluorescence	 imaging	 is	 its	 limited	penetration	depth;	fluorescence	 signal	
is	diminished	within	one	centimeter	tissue.	This	is	an	issue	due	to	the	retroperi-
toneal	location	of	the	pancreas.	But	again,	fusing	technologies	could	overcome	
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introduction
Advanced	 imwaging	 technologies,	 such	as	multidetector	computed	 tomogra-
phy	(mdct)	and	three-dimensional	magnetic	resonance	imaging	(3d-mri),	have	
























n i r fluorescence imaging systems and 
currently available fluorophores
nir	fluorescence	imaging	uses	nir	light,	which	is	safe	when	used	at	the	relative-







laparoscopic	 surgery.	 Most	 published	 clinical	 studies	 use	 the	 Photodynamic	












of	 tissue,	 revealing	structures	 just	below	 the	 tissue	surface.	Hereby,	 iatrogenic	
damage	to	vital	structures,	such	as	the	ureter	or	nerves	may	be	avoided	by	iden-
tification	 using	 nir	 fluorescence	 imaging.	 Research	 in	 the	 near	 future	will	 be	
necessary	to	determine	whether	this	technology	has	additional	value	in	order	to	
facilitate	the	surgical	procedure	and	improve	surgical	outcome.



























































sentinel lymph node mapping
Sentinel lymph node detection in vulvar cancer


































































However,	penetration	capacity	of	nir	fluorescence	 is	 limited	 to	approximately	
8	millimeters.	The	use	of	radiotracers	seems	therefore	still	indispensable,	since	





























In	6	out	of	 10	patients	 (60%),	 real-time	nir	fluorescence	 lymph	mapping	was	
observed,	resulting	in	the	detection	of	9	sln.	Ex	vivo,	11	out	of	197	lymph	nodes	
showed	nir	fluorescence	in	addition.	sln	metastases	were	found	only	in	1	patient	
(11%)	and	no	 false-negative	 slns	were	detected.	Although	 this	 shows	 the	 fea-
sibility	of	nir	fluorescence	imaging	in	sln	detection,	the	study	population	was	
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fluorophores	in	rats	and	pigs	[39].	They	studied	4,49-[(2-methoxy-1,4-phenylene)
di-(1e)-2,1-ethenediyl]bis-benzenamine	 (bmb)	 and	 4-[(1e)-2-[4-[(1e)-2-[4-amino-
phenyl]ethenyl]-3-methoxyphenyl]ethenyl]-benzonitrile	 (ge3082),	 which	 both	
accumulate	 in	 nerve	 tissue	 and	 emit	 light	 with	 wavelengths	 of	 560	 and	 600	




Intraoperative imaging and detection of ovarian cancer
Ovarian	cancer	is	the	fifth	cause	of	cancer	related	death	in	females	[6].	In	patients	
with	 clinically	 low	 stage	 disease,	 a	 staging	 procedure	 is	 performed	 to	 detect	
occult	tumor	spread	in	order	to	select	those	patients	who	need	chemotherapy	






cer	 in	normal	 sized	 lymph	nodes	or	discriminate	between	hyperplastic	 lymph	
nodes	 and	metastases;	 thirdly,	 the	provided	 images	do	not	provide	 real-time	
intraoperative	 guidance	 [44].	 Therefore,	 accuracy	 of	 preoperative	 staging	 by	
these	imaging	modalities	is	 limited.	The	only	reliable	staging	method	is	there-
fore	thorough	inspection	of	the	abdominal	cavity	by	laparoscopy	or	laparotomy	
and	histologic	 sampling.	This	 is	done	by	 taking	biopsies	of	 suspected	 lesions	
or	otherwise	at	random	[40].	However,	visual	and	tactile	information	is	not	ideal	
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conclusions
Current	 available	 literature	 suggests	 a	 complementary	 role	 for	 intraoperative	
nir	 fluorescence	 imaging	 in	 gynecological	 oncology.	 It	 has	 the	 potential	 to	




















































to	higher	 sensitivity	 and	a	broader	application	of	 the	 technology.	 In	addition,	
research	is	in	progress	to	conjugate	fluorophores	and	radiotracers	to	one	ligand,	



























Crane,	2010 10 cc 2	mL	icg	0.5	mg/mL 6	(60.0%) 9 0 100% 100%














icg 17	(85.0%) na3 1 50.0% 94.1%
Holloway,	2012 35 ec 2.5	mg	icg 34	(97.1%) 69 1 90.0% 96.2%





























Artemis Laser	diode	400-1000	nm,	4	mW/cm2 1.5	-	25 60 Yes Yes
fdpm	imager Laser	diode	785	±10	nm,	<1.9	mW/cm2 <76.2 Max	900 No No
Firefly	for	robotic	surgery na na na Yes No
flare led	745-779	nm,	14mw/cm2 45 3.7-169.5 Yes Yes
Fluobeam Laser	780	nm,	10	mW/cm2 22 80 Yes No
HyperEye led	760	nm,	power	ns 30-50 78.5 Yes Yes
Karl	Storz	high	definition
fluorescence	laparoscope Xenon	light,	760	nm Varies Varies Yes No
Kit-flare Laser,	660	nm,	760nm 17.8	–	33.0 7.6-14.0 Yes Yes
Mini-flare led	760	nm,	8.6	mW/cm2 30 100 Yes Yes
Munich/SurgOptix
prototype	camera	system Laser	750	nm,	300	mW 21 1.5-107	 Yes Yes
Photodynamic	Eye	(pde) Led	805	nm,	 12-25 na No No
pinpoint	Endoscopic
Fluorescence	Imaging na na na Yes Yes




Study n Injection Detection









Crane,	2011 10 1mL	icg	0,5mg/mL 10	(100%) 29 26	(89.7%) 28	(96.6%) 100% 100% 21	(72.4%)
Hutteman,	2012 9
1.6mL	of	500,	750	or	




µM	icg 19	(79.2%) 35 35	(100%) 35	(100%) 100% 100% 27	(77.1%)
Mathéron,	2013 152
icg-99m	Tc	









































     visualization
b) SLN resection
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Reprinted	by	permission	from	Elsevier:	The	Journal	of	Urology	[5].	©	2013.


































































































































































































































































































Chapter 30 in:Dip FD, Ishizawa T, Kokudo N and Rosenthal R, eds.  
Fluorescence Imaging for Surgeons (Springer): pp. 159-168
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Prognosis	 and	 survival	 of	 patients	with	 cancer	deteriorates	dramatically	when	
metastases	are	present.	Most	metastases	 in	 the	 liver	originate	 from	colorectal	
cancer.	14.5%	of	colorectal	cancer	patients	have	liver	metastases	at	the	moment	
of	diagnosis	and	15.2%	will	develop	 liver	metastases	within	5	years	after	cura-
tive	 resection	 of	 the	 primary	 tumor	 [1].	 Metastases	 are	 the	 leading	 cause	 of	
cancer-related	death,	with	no	 survivors	at	 5	 years	 if	 left	untreated	 [2].	Besides	
advancements	 in	 radiotherapy,	 (neoadjuvant)	chemotherapy	and	preoperative	











gins,	 extrahepatic	 disease,	 node-positive	 primary	 tumor,	 disease-free	 interval	
from	primary	tumor	to	metastases	less	than	12	months,	more	than	one	hepatic	











































Furthermore,	 liver	 tissue	 absorbs	 a	 higher	 proportion	 of	 nir	 fluorescent	 light	
compared	to	other	human	tissues,	such	as	colon	and	breast,	resulting	in	a	lower	
signal	[19].	Fluorophores	emitting	fluorescence	with	longer	wavelengths	achieve	












Conventional technologies for identification of metastases in the 
liver
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Dose and timing of icg administration
After	intravenous	injection,	icg	is	absorbed	by	hepatocytes	and	eventually	excret-
ed	into	the	bile.	Therefore,	the	first	period	after	intravenous	administration	results	












































allergy	and	 thyrotoxicosis	are	contraindications	 for	 its	use.	 icg	 is	not	metabo-
lized,	 is	 cleared	 exclusively	 by	 the	 liver	 and	does	 not	 undergo	 enterohepatic	







fluorescent	 signal.	 In	contrast,	 tumor-targeted	dyes	do	have	 this	property	and	
offer	therefore	great	advantages.	nir	fluorescence	imaging	of	metastases	in	the	
liver	 is	 challenging	due	 to	 hepatic	 uptake	 and	 clearance	of	many	 fluorescent	
dyes.	This	may	result	in	unfavorable	tumor-to-liver	ratio	(tlr).	For	identification,	














































































For	 colorectal	 liver	metastases,	 however,	 this	 technique	 is	 very	 useful,	 as	 col-
orectal	liver	metastases	are	mostly	located	on	the	surface	of	liver	parenchyma.	












































































































































pde 0.5	mg/kg	 i.v. 4	days	(1,2)		
&	2	days	(3)

















1 clm pde 500	µl	mixed	
with	ethanol	












7 clm pde 0.1	ml/kg na na 26/26 + 1 na
Peloso,		
2012




40 clm Mini-flare 10	and	20	
mg	














Figure	 1	 In	 vivo	 near-infrared	 fluorescence	 imaging	of	 a	 hepatic	metastasis	 using	 the	
Mini-flare	system	(Beth	Israel	Deaconess	Hospital,	Boston,	usa).	A	characteristic	rim	of	flu-
orescence	around	the	lesion	is	shown.
	 color		 nir	fluorescence	 color-nir	overlay	
	 color		 nir	fluorescence	 color-nir	overlay	
Figure	2	 Ex vivo	near-infrared	fluorescence	imaging	of	resected	and	sliced	lesion	at	pathology	
department	using	the	flare	imaging	system	(Beth	Israel	Deaconess	Hospital,	Boston,	usa).
	 color		 nir	fluorescence	 color-nir	overlay	
Figure	3	 Small,	superficial,	otherwise	occult	metastases	are	identified	by	near-infrared	flu-
orescence	imaging	(arrow).
	 color		 nir	fluorescence	 color-nir	overlay	
Figure	4	 Benign	lesions	(arrow)	can	be	differentiated	from	malignant	lesions	by	a	lack	of	a	
near-infrared	fluorescent	rim	around	the	lesion.
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characterized	 by	 the	 development	 of	 parathyroid,	 anterior	 pituitary	 and	 pan-
creatic	islet	cell	hyperplasia	and	microadenomas.[1]	 Its	primary	life-threatening	





resections.[4]	 Near-infrared	 (nir,	 wavelengths	 of	 700-900	 nm)	 fluorescence	
imaging	has	shown	to	identify	lesions	during	surgery	using	a	fluorescent	dye	and	
a	dedicated	imaging	system.[5]	Methylene	blue	(mb)	is	an	fda-approved	agent	













vided	 informed	consent.	During	 routine	 surgery,	 after	exposing	 the	pancreas,	
nir	fluorescence	imaging	was	performed	using	the	Quest	Spectrum™	Platform	
(Quest	Medical	 Imaging	 b.v.,	 The	Netherlands).	No	 autofluorescence	was	 ob	-
ser	ved	 (Figure	 2a).	 Subsequently,	 a	 dose	 of	 0.5	mg/kg	mb	was	 administered	











Multiple	 endocrine	 neoplasia	 type	 1	 syndrome	 (men1)	 can	 feature	 pancreatic	
neuroendocrine	lesions	that	have	the	potential	to	degenerate	into	malignancies	









regular	 follow-up.	 Intraoperative	 administration	 of	 mb	 allowed	 successful	 nir	
fluorescence	imaging	of	multiple	lesions	missed	by	preoperative	imaging.	After	
confirmation	by	intraoperative	ultrasound,	this	new	finding	led	to	a	major	change	
in	 treatment:	 from	 enucleations	 to	 total	 pancreatectomy.	 Histopathological	






















































Although	 in	 this	 case	mb	 and	 fluorescence	 imaging	 showed	 to	be	 specific	
for	neuroendocrine	lesions,	the	mechanism	of	action	is	unclear	and	potentially	
unreliable.	Furthermore,	its	wavelength	(around	700	nm)	is	subject	to	reduced	
tissue	penetration	depth	 and	more	 autofluorescence	 from	 surrounding	 tissue	
compared	to	the	more	optimal	wavelengths	around	800	nm.[5]	The	technique	







tion	and	 formalin	fixation.	White	arrows:	 lesions	 suspect	 for	pancreatic	neuroendocrine	
tumors.	*	Head	of	the	pancreas.	**	Tail	of	the	pancreas.	Dashed	arrow:	this	suspect	lesion	was	
stained	for	chromogranin	and	synaptophysin	(see	figure	3).
Figure	3	 Histopathological	examination	of	 a	 fluorescent	 lesion.	The	fluorescent	 lesion	
(dashed	arrow	in	figure	2b)	showed	strong,	diffuse	staining	for	synaptophysin	and	chro-
mogranin	in	100%	of	the	lesional	cells.	Magnification:	25x.
Figure	 1	 68Ga-dotatate	 pet/ct	 and	 intraoperative	ultrasound.	 68Ga-dotatate	 pet/ct	
identified	multiple	metabolically	active	lesions	in	the	head,	body	and	tail	of	the	pancreas.	
Intraoperative	 ultrasound	 confirmed	 the	 presence	 of	 multiple	 neuroendocrine	 lesions	
throughout	the	whole	pancreas.	White	arrows:	lesions	suspect	for	pancreatic	neuroendo-
crine	lesions.	Smaller	microadenomas	have	not	been	marked.
	 color		 nir	fluorescence	 color-nir	merge	
	 he		 chromogranin	 synaptophysin	
a
b 












































































































































































Mean	 time	 between	 injection	 and	 end	 of	 the	 procedure,	 i.e.	 the	 time	 for	
icg:nanocolloid	to	migrate	to	the	sln,	was	189	±	48	minutes.	During	the	proce-
dure,	a	mean	of	2.0	±	0.82	fluorescent	lns	could	be	visualized	(Fig.	2).	Ex vivo 








outcome,	 but	 also	 to	 challenges.	 Laparoscopic	 surgery	 results	 in	 significantly	
lower	mortality	and	morbidity	compared	to	open	surgery	[25],	but	also	deprives	








The	present	 study	 shows	 that	endoscopic	 tattooing	with	 icg:nanocolloid	 is	









Laparoscopic fluorescence imaging system
Intraoperative	 nir	 fluorescence	 imaging	 was	 performed	 using	 a	 laparoscop-




Preparation and injection of the probe
icg	(25	mg	vials,	Pulsion	Medical	Systems,	Munich,	Germany)	was	dissolved	in	
5ml	sterile	water.	Subsequently,	1	ml	of	5	mg/ml	icg	was	diluted	in	100	ml	ster-
ile	water	(50	µg/ml final concentration). Nanocolloid (0.5	mg	vials,	ge	Healthcare,	
Eindhoven,	the	Netherlands)	was	dissolved	in	3	ml	saline.	1.5	ml	50	µg/ml icg was 
then mixed with 0.9	ml	of	0.167	mg/ml	nanocolloid.	After	general	anesthesia,	













flare™	 imaging	 system	 [24].	 Fluorescent	 lns	 were	 appointed	 as	 slns	 and	
























as	sln	tracers	in	in vivo	and ex vivo	settings,	but	both	tracers	have	disadvantag-


























icg	 is	 not	 a	 tumor-targeted	probe.	Hence,	 no	 tumor-specific	 signal	 can	be	
expected.	The	accuracy	of	the	fluorescence	signal	depends	therefore	mainly	on	
the	accuracy	of	the	gastroenterologist’s	injection.	In	the	near	future,	tumor-specific	



























































































































1 M 71 cT2N0M0 15 Radiotherapy + 5 12 +
2 M 61 cT3N2M0 7 Chemoradiotherapy + 2 15 +
3 F 65 cT3N1M0 18 Radiotherapy + 3 12 +
4 F 70 cT3N2M0 7 Chemoradiotherapy - 5 18 +
5 F 76 cT2N0M0 9 None + 4 26 +








	 color		 nir	fluorescence	 color-nir	merge	































































































































































































and	 intraoperative	 imaging	 techniques	 have	 low	 sensitivity	 for	 subcentimeter	
















Parallels	 can	be	drawn	between	5-ala	 for	glioma	surgery	and	 indocyanine	
green	(icg,	emission	peak	at	820	nm)	for	resection	of	crlm,	even	though	the	dis-
eases	and	consequences	are	different.	nirf	 imaging	using	icg	 identifies	(sub)






















methods First,	 patients	 undergoing	 resection	 of	 crlm	 with	 or	 without	 nirf	
imaging	were	analyzed	retrospectively.	Perioperative	details,	liver-specific	recur-
rence-free	interval	and	overall	survival	were	compared.	Second,	the	prognosis	
of	patients	 in	whom	additional	metastases	were	 identified	 solely	by	nirf	was	
studied.
results Eighty-six	 patients	 underwent	 resection	 with	 nirf	 imaging	 and	 87	





















only),	 followed	by	 intraoperative	ultrasound	 (ious)	performed	by	a	dedicated	
radiologist.	Subsequently,	the	accessible	liver	surface	of	patients	in	the	experimen-
tal	cohorts	was	screened	by	nirf	imaging.	Note	that	with	the	currently	available	
systems,	only	 the	 accessible	 surface	of	 the	 liver	was	 interrogated.	Metastases	
were	considered	additionally	identified	if	they	were	not	detected	by	any	type	of	
preoperative	imaging.	They	were	classified	by	their	method	of	detection:	stan-
dard	(inspection,	palpation	and/or	 ious)	or	nirf	 imaging	alone.	 Intraoperative	


















Survival after resection of metastases identified solely by nirf 
imaging (Analysis 2)
An	additional	 cohort,	 termed	 ‘analysis	 2’,	was	 created	 to	 answer	 the	question	
whether	 the	(micro)metastases	additionally	 identified	by	nirf	are	 indicative	of	
otherwise	undetectable,	widespread	metastases	in	the	liver	or	if	patients	are	in	
fact	cured	by	resecting	these	lesions.	Only	patients	in	whom	additional	lesions	





























Preoperative workup and surgical procedure (analysis 1)
All	 patients	 underwent	 computed	 tomography	 (ct)	 to	 detect	 hepatic	 and/or	
extrahepatic	metastases.	In	selected	cases,	when	deemed	necessary	by	the	med-
ical	team,	magnetic	resonance	imaging	(mri)	or	positron	emission	tomography	
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standard-of-care	since	2013,	resulting	in	a	significant	difference	between	the	lumc	
and	 smgh	 experimental	 cohorts.	 Furthermore,	 patients	 from	 smgh	 had	more	
comorbidity,	including	copd,	diabetes	and	cardiovascular	events,	resulting	in	a	
significantly	higher	asa	score.




Tumor characteristics (Analysis 1)
Tumors	 resected	 in	 the	 lumc	experimental	 cohort	were	compared	with	 those	















tification	 of	 additional	 crlm	 was	 not	 significantly	 correlated	 with	 the	 interval	
between	last	preoperative	imaging	and	surgery.

















Baseline	 characteristics	 between	 cohorts	 were	 compared	 using	 an	 unpaired	
samples	T-test	for	parametric	continuous	data,	Mann-Whitney	U-test	for	non-para-
metric	 continuous	 data	 and	 a	 Pearson’s	 Chi-square	 test	 for	 dichotomous	 or	
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Although	 significantly	more	 tumors	were	 identified	 in	 the	 lumc	 experimental	
cohort,	patients	still	developed	recurrences,	of	which	the	majority	within	the	first	







































Survival after resection of metastases identified solely by nirf 
imaging (Analysis 2)








detected	easily,	 neither	before	nor	during	 surgery.[5-7,	 17]	 Even	with	 state-of-
the-art	scanners	and	up-to-date	protocols,	metastases	are	still	being	missed,	as	
experienced	 in	 this	study.	Moreover,	metastases	may	arise	and/or	grow	 in	 the	
period	between	preoperative	 imaging	and	surgery.	Novel	 techniques	 for	bet-
ter	intraoperative	distinction	between	malignant	and	benign	tissue	are	urgently	
needed.	This	is	the	first	study	that	presents	long-term	follow-up	after	nirf-guid-
ed	 resection	 of	 crlm,	 although	 the	 non-randomized	design	 limits	 its	 level	 of	
evidence.	 nirf	 imaging	 of	 crlm	 using	 icg	 was	 safe	 and	 time-efficient,	 while	
significantly	more	and	smaller	tumors	were	identified	during	surgery.	Removal	
of	metastases	solely	identified	by	nirf	appears	helpful;	52%	of	patients	did	not	




























In	conclusion,	 this	 study	suggests	 that	nirf	 imaging	during	 resection	of	crlm	
identifies	 significantly	 more	 and	 smaller	 tumors,	 preventing	 recurrences	 in	 a	
subset	of	patients.	Given	its	safety	profile	and	low	expense,	routine	use	can	be	



































PERCENTAGE OF PATIENTS IN WHOM 
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Type of surgery  0.06
Laparotomy 94	(82/87) 85	(57/67) 100	(19/19)
Laparoscopy 5	(4/87) 15	(10/67) 0	(0/19)
Conversion	to	laparotomy 1	(1/87) 0	(0/67) 0	(0/19)
Hemihepatectomy 16	(14/87) 10	(7/67) 0.31 32	(6/19)
rfa 28	(24/87) 24	(16/67) 0.60 5	(1/19)
Node	positive	primary* 51	(44/86) 56	(36/64) 0.54 68	(13/19)
Disease-free	interval	<	12	months* 76	(66/87) 78	(52/67) 0.80 68	(13/19)
More	than	1	hepatic	tumor* 59	(51/87) 49	(33/67) 0.25 42	(8/19)
Largest	hepatic	tumor	>	5cm* 14	(12/87) 9	(6/67) 0.35 21	(4/19)
Preoperative	cea	>	200ng/ml* 3	(2/72) 2	(1/55) 0.72 11	(2/19)
Synchronous	metastases 53	(46/87) 43	(29/67) 0.24 32	(6/19)
No.	of	crlm	on	ct/mri,	median; range (n) 1	;	1	-	5	(67) 2	;	1	-	7	(87) 0.48 1	;	1	-	4	(19)
Comorbidities  0.25
copd 5	(4/87) 1	(1/67) 26	(5/19)
dvt	or	pe 2	(2/87) 3	(2/67) 11	(2/19)
cve 9	(8/87) 1	(1/67) 42	(8/19)
dm 10	(9/87) 7	(5/67) 74	(14/19)





















 Female 36	(31/87) 43	(29/67) 42	(8/19)
 Male 64	(56/87) 57	(38/67) 58	(11/19)
Age	at	surgery,	mean ± sd (n) 63	±	9.4	(87) 62	±	9.2	(67) 0.55 61	±	9.3	(19)
Chemotherapy  0.42
 No	chemotherapy 28	(24/87) 36	(24/67) 0	(0/19)
 Neoadjuvant 40	(35/87) 40	(27/67) 26	(5/19)
 Adjuvant 32	(28/87) 24	(16/67) 74	(14/19)
Location of primary tumor  
 Colon 33	(28/86) 40	(24/67) 42	(8/19)
 Sigmoid 42	(36/86) 28	(19/67) 37	(7/19)
 Rectum 26	(22/86) 36	(24/67) 21	(4/19)
Latest type of preoperative imaging  0.09
ct 70	(61/87) 61	(41/67) 100	(100/19)
pet-ct 7	(6/87) 1	(1/67) 0	(0/19)
mri 13	(11/87) 15	(10/67) 0	(0/19)
Primovist-enhanced	mri 10	(9/87) 22	(15/67) 0	(0/19)
Days	between	imaging		
and	surgery,	mean ± sd (n) 34	±	18	(87) 38	±	24	(67) 0.24 na
asa score  0.52
i 12	(10/86) 9	(6/67) 0	(0/19)
ii 80	(69/86) 78	(52/67) 53	(10/19)
iii 8	(7/86) 13	(9/67) 47	(9/19)



























































































































mean ± sd (n)
lumc Experi- 
mental (n=67) 
mean ± sd (n)
p-value 
Total	resected	volume	(cm³)	/	number	of	vital	tumors	resected  
Other* 62	±	3.8	(66) 57	±	4.5	(54) 0.76
Hemihepatectomy* 637	±	2.4	(12) 657	±	2.7	(7) 0.95
Volume	of	healthy	tissue	resected	per	tumor	(cm³)**  
Other* 26	±	4.9	(128) 24	±	7.5	(110) 0.79
Hemihepatectomy* 685	±	2.2	(16) 596	±	1.9	(11) 0.62
Length	of	surgery	(min) 180	±	53	(87) 183	±	56	(67) 0.69
Estimated	blood	loss	(ml)* 403	±	2.8	(63) 416	±	3.3	(48) 0.89
Duration	of	hospital	stay	(days)	-	median ; range (n) 6	;	1	-	48	(87) 6	;	4	-	87	(67) 0.99
Reoperation	-	% (n/n) 7	(6/87) 7	(5/67) 0.89





































































































The	 yield	of	 sl	may	be	 amplified	by	 adding	 laparoscopic	 ultrasonography	














introduction Up	 to	 38%	 of	 pancreatic	 and	 periampullary	 cancer	 patients	
undergoing	 curative	 intended	 surgery	 turn	 out	 to	 have	 incurable	 disease.	




methods All	 patients	 undergoing	 curative	 intended	 surgery	 of	 pancreatic	




























































Medical	Center	 (lumc)	were	eligible	 for	 inclusion.	Exclusion	criteria	were	con-
traindications	for	icg	administration:	egfr	<55;	hyperthyroidism;	and	allergy	to	






















































Reduced	 icg	clearance	 results	 in	nonspecific	background	fluorescence,	which	






























Quality of near-infrared fluorescence imaging














































































































































































































* The tumor could not be measured 
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Recently,	 several	 clinical	 studies	 with	 tumour-targeted	 fluorescent	 tracers	
demonstrated	 the	 feasibility	 to	 visualize	 tumours,	 and	more	 importantly	 their	
margins,	during	surgery	 [6-8].	Cetuximab	was	conjugated	 to	 the	near-infrared	
fluorescent	dye	irdye800cw.	The	combination	enabled	demarcation	of	tumours	
with	millimetre-resolution	in	oral	cancer	patients	[9].	These	results	are	promising,	
but	 these	 tracers	have	several	disadvantages.	First,	 intravenous	administration	
may	lead	to	adverse	reactions.	Cetuximab,	for	example,	can	cause	severe	infu-
sion	reactions	and	other	harmful	side	effects	[10].	Second,	antibody-based	tracers	









All	 these	 issues	can	be	solved	by	 topically	applying	activatable	fluorescent	
tracers	 instead.	This	 strategy	 requires	a	much	 lower	dose	and	does	not	 suffer	










materials	 and	methods	 The	preclinical	Maestro	and	clinical	Artemis	 imag-













conclusion	 This	 study	demonstrates	 the	 feasibility	 to	detect	 tumor-positive	
resection	margins	with	gglu-hmrg	and	a	clinical	fluorescence	imaging	system.	
Applying	 this	 technique	 would	 enable	 intraoperative	 screening	 of	 the	 entire	
resection	margin	and	allow	direct	re-resection	in	case	of	tumor-positivity.








the	background	and	fluorophore	 are	 separated.	The	 software	quantifies	each	
pixel	and	determines	 relative	concentration	of	 the	fluorophore	present	 in	 that	
pixel	[17,	18].
The	Artemis	fluorescence	 imaging	system	[16]	 (Quest	Medical	 Imaging	B.V.,	
























Recently,	 γ-glutamyl	 hydroxymethyl	 rhodamine	 green	 (gglu-hmrg)	was	 devel-
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results

































































Directly	after	surgery	 the	 resection	margins	of	 the	 resected	specimen	were	
sprayed	with	1	ml	of	50	µM	gglu-hrmg	per	6	cm2.	Upcoming	fluorescent	spots	
were	 marked	 with	 ink.	 Subsequently,	 the	 epithelial	 side	 was	 sprayed,	 which	
functioned	as	a	positive	control.	Fluorescence	imaging	was	performed	with	the	
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be	better	if	also	the	in vivo	resection	margin	could	be	screened	with	gglu-hmrg.	
This	 requires	certain	 toxicology	 studies	prior	 to	human	use,	but	 topical	appli-




















The	fluorescence	signals	did	not	align	perfectly	 in	all	ex vivo	 frozen	 tissues	
(Figure	4).	There	are	several	explanations.	Tissue	slices	 sprayed	with	gglu-hm-
rg	stained	afterwards	negative	for	ggt.	We	therefore	used	consecutive,	but	not	






















Ex vivo evaluation of resection margins during oral cancer surgery
Seven	 patients	 undergoing	 surgery	 for	 suspected	 oral	 cancer	 were	 included	
(Table	2).	 In	 three	patients	fluorescence	was	observed	at	 the	resection	margin	























survival	would	 also	help	 validate	 this	 tool.,	where	we	 could	diagnose	 tumour	



















Discrimination	 between	 zero	 measurements	 and	 activated	 fluorescence	
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Negative Weak Positive Negative Weak Positive
ggt Negative 6 5 2 ggt Negative 0 0 0
Weak 2 0 0 Weak 0 2 3





No. Diagnosis Margin rm es
1 Keratinizing	squamous	cell	carcinoma Clear	(8	mm) - + +
2 Parakeratosis,	hyperplasia na - - -
3 Keratinizing	squamous	cell	carcinoma Tumour-positive + + +
4 Keratinizing	squamous	cell	carcinoma Tumour-positive + ++ +
5 Keratinizing	squamous	cell	carcinoma Clear	(8	mm) - + +
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beled	 ligands	 have	 been	 introduced	 in	 clinical	 trials,	 including	 the	 labeled	
antibodies	cetuximab-irdye800cw	[4]	for	the	epidermal	growth	factor	receptor	
(egfr),	 bevacizumab-irdye800cw	 (ClinicalTrials.gov	 Identifier	 nct01508572)	

































This	 study	 evaluated	 the	 tumor-targeted	 zwitterionic	 near-infrared	 fluorescent	
peptide	 crgd-zw800-1	 as	 tracer	 for	 intraoperative	 imaging	 of	multiple	 can-
cer	types.	crgd-zw800-1	was	validated	in vitro	on	glioblastoma	(u-87	mg)	and	
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As	 described	before,	 at	 24	 h	 the	 intensity	 of	 fluorescence	 signals	 in	 ht-29	
tumors	 decreased	 compared	 to	 4	 h	 (Figure	 5c).	 However,	 in	 all	 dose	 groups	













Binding assay and in vitro and in vivo competition experiments












Identification of off-target interactions
Out	of	44	selected	targets,	crgd-zw800-1	resulted	in	significant	inhibition	(62%)	
of	control-specific	binding	of	cyclooxygenase-2	(cox-2).	Weak	to	moderate	inhi-
bition	was	 seen	 in	5-hydroxytryptamine	 (serotonin)	 receptor	 2b	 (5-ht2b,	 29%),	
lymphocyte-specific	protein	tyrosine	kinase	(lck,	28%),	and	dopamine	receptor	
D2s	(22%)	(Table	s1,	supplementary	data).
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irdye800cw,	cy5.5,	or	 icg	 is	 feasible,	but	compared	to	crgd-zw800-1	these	
tracers	show	higher	non-specific	uptake	in	normal	tissues	and	organs	due	to	their	






































































(icg),	 irdye800cw,	and	cy5.5	 for	optical	 imaging	applications	 [21-25].	A	study	
using	crgd-irdye800cw	showed	delineation	of	u-87	mg	tumors	 in	mice	and	
underscored	 the	 relative	 simplicity	and	 low	cost	of	 the	synthesis	 [21].	Another	




sion	 of	 rgd-binding	 integrins	 by	 tumor-associated	 vascular	 endothelium	 and	
stromal	 cells.	 nir	 fluorescence	 imaging	 of	 tumors	 using	 crgd	 conjugated	 to	
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rgd	 integrin-binding	 site	 is	 evolutionary	 conserved	 in	 vertebrates,	 including	
humans,	mice,	 and	 rats	 [34].	Due	 to	 these	 similarities,	 animal	models	provide	
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twice	and	 imaged	with	 the	Odyssey	nir	 scanner	 (li-cor	Biosciences,	 Lincoln,	
Nebraska:	focus	offset	3	mm;	800-nm	channel).	Next,	cells	were	permeabilized	
with	a	40/60	mixture	of	acetone	and	methanol	followed	by	a	washing	step	and	
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Dose (nmol)
	 		 	 color-nir	
	 color	 nir	 merge	
a.	imaging	of	pancreatic	cancer	(flare®)
	 		 	 	
	 he	 dapi		 nir
	 		 	 color-nir	
	 color	 nir	 merge	
c.	imaging	of	oral	cancer	(flare®)
	 he	 dapi		 nir
b.	imaging	at	4	h	post	injection	(pearl®)
d.	imaging	at	24	h	post	injection	(pearl®)
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  u-87 mg ht-29 mcf-7 bxpc-3 osc-19
αvβ3 59,500 0 0 4,500 0
αvβ5	 17,500 32,500 19,500 4,000 2,000











38.0	±	8.9 25.3	±6.4 14.6	±	1.7 71.1	±	9.4 0.25	±	0.06
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introduction
Intraoperative	 near-infrared	 (nir)	 fluorescence	 imaging	 is	 in	 the	 midst	 of	 a	
Renaissance.	Multiple	 imaging	systems	are	commercially	available	 for	preclin-
ical	 and	 clinical	 purposes	 and	 their	 sensitivity	 has	 improved	 greatly	 over	 the	
past	years.	However,	success	of	these	systems	goes	hand-in-hand	with	the	qual-
ity	of	nir	fluorophores.	An	important	challenge	in	nir	fluorescence	imaging	is	




hepatic	 clearance,	 resulting	 in	 high	 uptake	 in	 liver	 and	 contamination	 of	 the	
gastrointestinal	 (gi)	 tract.[2]	Moreover,	 icg	 cannot	be	 conjugated	 to	 targeting	
moieties.	 Other	 anionic	 fluorophores,	 including	 irdye800cw	 and	 cy5.5,	 are	
conjugatable,	but	show	similar	uptake	in	the	liver	and	the	gi	tract.[3]	Elimination	
patterns	are	important	especially	when	imaging	gi	tumors,	e.g.	colorectal,	pan-




rats	 demonstrated	 that	 the	 ureters	 became	 fluorescent	 within	 minutes	 after	
a	 low	dose	of	 zw800-1	and	 remained	visible	 for	 several	hours.	These	charac-
























methods	 zw800-1	 and	 crgd-zw800-1	 were	 studied	 separately.	 Preclinical	
toxicology	 studies	 were	 performed	 to	 assess	 a	 safe	 starting	 dose	 for	 first-in-
human	 studies.	 Subsequently,	 safety,	 tolerability	 and	 pharmacokinetics	 were	
assessed	in	two	phase	1	studies	in	healthy	volunteers.	We	performed	randomized,	








































Peptide	 Laboratory	of	 the	 Interdivisional	gmp	 Facility	 of	 the	 Leiden	University	



































designed	 to	 determine	 the	 tolerability	 and	 pharmacokinetics	 in	 humans.	 The	


















































































































morbidity	and	mortality	 rates.[14]	Although	advances	 in	preoperative	 imaging	



































no	findings	on	 clinical	pathology,	or	microscopic	 findings	 indicating	 cause	of	
death	 were	 noted.	 Routine	 hematology	 parameters	 and	 clinical	 biochemistry	
remained	within	the	normal	range	and	were	considered	not	toxicologically	rel-
evant.	Histopathological	examination	did	not	raise	a	safety	signal.	Microscopic	
findings	 at	 the	 injection	 site	 (tail	 vein)	 included	 perivascular	 inflammation,	
perivascular	 hemorrhage	 and	 vascular	 necrosis	 and	 were	 present	 at	 similar	
incidence	and	severity	in	control	and	treated	rats.	These	were	considered	pro-
cedure-related	rather	than	treatment-related.


































ing	 time.	Based	on	preclinical	and	clinical	 results,	 it	 is	expected	 that	 sbrs	 are	






and	zw800-1,	 surgeons	have	 the	potential	 to	 increase	 radical	 resection	 rates,	
while	reducing	avoidable	iatrogenic	damage.
	 	 	 	 	 	 	Translational	 studies	 are	 costly	 and	 time-consuming.	This	 study	demon-
strates	that	there	are	several	strategies	to	do	so.	For	zw800-1,	the	total	package	
of	 toxicology	 studies	was	 performed,	 including	 the	 assessment	 of	 the	 noael	
and	mtd.	Especially	the	latter	costed	huge	amount	of	zw800-1.	The	results	were	
not	 really	meaningful;	 the	anticipated	dose	 for	clinical	studies	was	well	below	
the	 safe	 starting	 dose	 assessed	 in	 the	 toxicology	 studies.	 Therapeutic	 drugs	
often	 require	a	maximally	 tolerated	dose	 to	sort	optimal	effect.	Optimal	 intra-







































































































































































































































the	difference	between	well-perfused	 tissue	and	areas	 that	are	deprived	 from	
blood	flow.	Anastomotic	 leakage	after	colorectal	surgery	 is	a	feared	complica-
tion	with	high	morbidity	and	mortality	 rates.	nirf	assessment	of	anastomoses	
can	 influence	 intraoperative	 decision-making	 and	 potentially	 prevent	 anasto-
motic	leakage	caused	by	ischemia	[10].	Multiple	injections	of	icg	can	be	given	
during	surgery,	since	icg	has	a	short	serum	half-life.	Currently,	a	multicenter	study	
is	performed	 to	determine	 the	difference	 in	anastomotic	 leakage	 rate	with	or	
without	nirf	assessment	after	low	anterior	resections	(clinicaltrials.gov	number	
nct02205307).
icg	 is	 cleared	exclusively	by	 the	 liver	 [11].	Within	minutes	 after	 intravenous	
administration	the	liver	becomes	fluorescent.	icg	is	subsequently	excreted	into	










injuries.	However,	 designing	 a	 study	 to	determine	 if	 bile	duct	 injuries	 can	be	
prevented	would	require	a	huge	amount	of	patients.	A	multicenter	randomized	








to	 standard-of-care,	 nirf	 imaging	 identifies	 significantly	 more	 and	 smaller	
hepatic	 metastases	 of	 colorectal	 cancer,	 without	 safety	 concerns	 or	 delaying	
Surgery	is	the	cornerstone	of	curative	treatment	of	many	malignancies.	However,	
incomplete	resections	and	avoidable	iatrogenic	damage	during	surgery	increase	





















imaging	 research	 to	get	momentum	 (chapter	 2	 and	3).	 nirf	 imaging	 systems	



























	» structure-inherent	 targeted	 fluorophores,	 single	 compact	 molecules	 which	
both	target	and	fluoresce	[26].
Fluorophores conjugated to ligands
The	first	exploratory	clinical	study	was	performed	with	the	folate	receptor	α	(frα)	
specific	fluorescent	tracer	ec17	that	consists	of	the	fluorophore	fluorescein	iso-










































































The	 future	of	nirf	 imaging	seems	promising.	Several	fluorescent	 tracers	have	
proven	 their	 effectiveness	 and	 are	 moving	 towards	 phase	 3	 clinical	 trials.	
Simultaneously,	 sensitive,	 handy,	 and	 ce-marked	 imaging	 systems	 have	 been	



















































A	 disadvantage	 of	 “always-on”	 fluorophores	 is	 that	 unbound	 tracers	 in	 the	
background	cause	non-specific	fluorescence,	which	 results	 in	 lower	 tumor-to-
background	ratios.	Reducing	nonspecific	background	fluorescence	is	important	
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Broaden the applicability


























































































































































































































































































































































































neuroendocriene	tumoren	blauw	verkleuren.	 In	deze	casus	 is	een	relatief	 lage	
dosering	methyleen	 blauw	 peroperatief	 toegediend,	 waarna	met	 fluorescen-
tiebeeldvorming	de	afwijkingen	duidelijk	zichtbaar	werden.	Hoofdstuk 5 toont	
aan	dat	 icg	 ook	gebruikt	kan	worden	om	tumoren	 te	markeren.	Tijdens	 lapa-
roscopische	 rectumchirurgie	 is	 het	 lastig	 om	 de	 tumor	 te	 lokaliseren.	 De	
gastro-enteroloog	 markeert	 preoperatief	 endoscopisch	 de	 locatie	 met	 inkt.	





































of	 gezond	 is.	Deze	 interpretatie	 is	 echter	 lastig,	 variabel	 en	 subjectief.	Nabij-
infrarode	fluorescentiebeeldvorming	is	een	techniek	die	structuren	in	real-time	



















tijdens	 gynaecologische	 ingrepen.	 Met	 behulp	 van	 indocyanine	 groen	 (icg)	
kunnen	schildwachtklieren	beter	gevonden	worden.	Een	meta-analyse	van	de	
literatuur	 toont	dat	met	behulp	van	 icg	er	meer	schildwachtklieren	gevonden	
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Fluorescentiebeeldvorming	 is	 in	 staat	 om	 intra-operatief	 het	 contrast	 van	
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